Latest frontiers in pharmacotherapy for benign prostatic hyperplasia

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
Kazuki Kawabe

Abstract

Alpha(1)-adrenoceptor antagonists, called alpha(1)-blockers, are the first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Nonselective alpha(1)-blockers like prazosin were mainly used in the past, but prostate-specific alpha(1)-blockers such as tamsulosin or naftopidil are now the mainstream agents for the management of BPH, based on the function of alpha(1)-adrenoceptor subtypes. Recent studies on voiding dysfunction have clarified the association between BPH and overactive bladder (OAB), underlining the use of OAB treatment in the management of BPH, inducing the simultaneous administration of antimuscarinic agents. Every aspect of diversified BPH symptom can be controlled individually in a short period.

References

Jul 1, 1996·International Journal of Urology : Official Journal of the Japanese Urological Association·Y HommaY Ohashi
Feb 22, 2002·Neurourology and Urodynamics·Paul AbramsUNKNOWN Standardisation Sub-committee of the International Continence Society
Dec 19, 2003·The New England Journal of Medicine·John D McConnellUNKNOWN Medical Therapy of Prostatic Symptoms (MTOPS) Research Group
Aug 18, 2004·The Journal of Urology·Nobuyuki GoyaHiroshi Toma
Oct 14, 2004·International Journal of Urology : Official Journal of the Japanese Urological Association·Kentaro IchiokaYoichi Arai
Jun 11, 2005·The Journal of Urology·Qin ChenTadaichi Kitamura
Mar 28, 2006·International Journal of Urology : Official Journal of the Japanese Urological Association·Kazuki KawabeUNKNOWN TAMSULOSIN LONG-TERM STUDY GROUP*

❮ Previous
Next ❯

Citations

Nov 11, 2008·Biomedical Research·Haruko YanaseMasahito Kawatani
Oct 6, 2007·International Journal of Cancer. Journal International Du Cancer·Hideki KandaYoshiki Sugimura
Mar 16, 2019·Journal of Cellular and Molecular Medicine·Hirokazu UrushiyamaTakahide Nagase
Nov 4, 2017·Journal of Cancer Research and Clinical Oncology·Kenichiro IshiiYoshiki Sugimura
Mar 1, 2017·Journal of Cancer Research and Clinical Oncology·Yoichi IwamotoYoshiki Sugimura

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.